The hemostatic defect of cardiopulmonary bypass.
Cardiac surgery involving cardiopulmonary bypass is a common yet complex procedure that results in considerable disruption of hemostasis during and following surgery. Despite the relatively common and widespread use of this procedure, there remains a significant peri-operative risk of both thrombosis and hemorrhage in some patients. This is known as the hemostatic defect of cardiopulmonary bypass. Strategies including the use of pharmacological agents, hemodilution, autologous blood transfusion, rapid in-theatre monitoring of hemostatic potential with fine-tuning of the degree of heparinization, minimally invasive surgery and the use of biologically coated cardiopulmonary bypass equipment have been employed to ameliorate the effects of cardiopulmonary bypass on hemostasis. However there exists a fine line between preventing hemorrhage and promoting thrombosis. Likewise attempts to prevent thrombosis may result in increased hemorrhage. Research into many strategies for minimizing the hemostatic defect of cardiopulmonary bypass is incomplete, with safety and efficacy the subjects of intensive investigation.
Linden
Matthew Dean
MD
Center for Platelet Function Studies, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA. matthew.linden@umassmed.edu
D001791:Blood Platelet Disorders / Q000139:chemically induced; D002315:Cardiopulmonary Bypass / Q000009:adverse effects* / Q000379:methods; D005342:Fibrinolysis; D006438:Hemodilution; D006470:Hemorrhage / Q000139:chemically induced; D006487:Hemostasis; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans
D006493:Heparin